BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,096 filers reported holding BAXTER INTL INC in Q4 2020. The put-call ratio across all filers is 0.87 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $30,758 | -17.1% | 815 | 0.0% | 0.00% | -25.0% |
| Q2 2023 | $37,123 | +12.3% | 815 | 0.0% | 0.00% | +33.3% |
| Q1 2023 | $33,048 | -20.4% | 815 | 0.0% | 0.00% | -40.0% |
| Q4 2022 | $41,541 | -5.6% | 815 | 0.0% | 0.01% | 0.0% |
| Q3 2022 | $44,000 | -84.8% | 815 | -81.9% | 0.01% | -80.0% |
| Q2 2022 | $290,000 | -17.1% | 4,515 | 0.0% | 0.02% | +8.7% |
| Q1 2022 | $350,000 | -9.8% | 4,515 | 0.0% | 0.02% | -8.0% |
| Q4 2021 | $388,000 | -41.3% | 4,515 | -45.0% | 0.02% | -39.0% |
| Q3 2021 | $661,000 | -16.3% | 8,215 | -16.3% | 0.04% | -12.8% |
| Q2 2021 | $790,000 | +21.4% | 9,815 | +27.2% | 0.05% | +4.4% |
| Q1 2021 | $651,000 | +5.2% | 7,715 | 0.0% | 0.04% | -15.1% |
| Q4 2020 | $619,000 | +66.8% | 7,715 | +67.2% | 0.05% | +32.5% |
| Q3 2020 | $371,000 | -32.8% | 4,615 | -28.1% | 0.04% | -36.5% |
| Q2 2020 | $552,000 | +33.0% | 6,415 | +25.4% | 0.06% | +8.6% |
| Q1 2020 | $415,000 | +41.2% | 5,115 | +45.5% | 0.06% | +65.7% |
| Q4 2019 | $294,000 | -42.2% | 3,515 | -39.6% | 0.04% | -41.7% |
| Q3 2019 | $509,000 | +6.9% | 5,815 | 0.0% | 0.06% | +3.4% |
| Q2 2019 | $476,000 | +29.7% | 5,815 | +28.8% | 0.06% | +20.8% |
| Q1 2019 | $367,000 | -75.9% | 4,515 | -80.5% | 0.05% | -78.9% |
| Q4 2018 | $1,521,000 | -14.6% | 23,115 | 0.0% | 0.23% | +7.1% |
| Q3 2018 | $1,782,000 | -23.2% | 23,115 | -26.4% | 0.21% | +0.5% |
| Q2 2018 | $2,319,000 | +20.4% | 31,415 | +6.1% | 0.21% | +13.4% |
| Q1 2018 | $1,926,000 | +0.6% | 29,615 | 0.0% | 0.19% | +1.6% |
| Q4 2017 | $1,914,000 | -7.6% | 29,615 | -10.3% | 0.18% | -1.6% |
| Q3 2017 | $2,072,000 | +3.7% | 33,015 | 0.0% | 0.19% | +1.6% |
| Q2 2017 | $1,999,000 | +16.8% | 33,015 | 0.0% | 0.18% | +14.4% |
| Q1 2017 | $1,712,000 | -31.2% | 33,015 | -41.2% | 0.16% | +26.0% |
| Q4 2016 | $2,488,000 | -34.8% | 56,115 | -41.4% | 0.13% | -31.7% |
| Q3 2016 | $3,816,000 | +17.2% | 95,689 | +32.9% | 0.19% | +29.2% |
| Q2 2016 | $3,257,000 | +7.4% | 72,015 | -2.5% | 0.14% | +1.4% |
| Q1 2016 | $3,033,000 | +23.0% | 73,829 | +14.2% | 0.14% | +22.4% |
| Q4 2015 | $2,465,000 | +16.1% | 64,629 | 0.0% | 0.12% | +3.6% |
| Q3 2015 | $2,123,000 | -53.0% | 64,629 | 0.0% | 0.11% | -49.3% |
| Q2 2015 | $4,519,000 | +2.1% | 64,629 | 0.0% | 0.22% | +1.8% |
| Q1 2015 | $4,427,000 | -7.8% | 64,629 | -1.4% | 0.22% | -3.6% |
| Q4 2014 | $4,803,000 | -20.8% | 65,529 | -22.5% | 0.22% | -1.7% |
| Q3 2014 | $6,067,000 | -12.6% | 84,529 | -12.0% | 0.23% | -8.4% |
| Q2 2014 | $6,943,000 | +3.8% | 96,029 | +5.6% | 0.25% | -0.4% |
| Q1 2014 | $6,690,000 | +645.8% | 90,929 | +604.9% | 0.25% | -56.7% |
| Q4 2013 | $897,000 | -15.7% | 12,900 | -20.4% | 0.58% | -21.2% |
| Q3 2013 | $1,064,000 | -5.2% | 16,200 | 0.0% | 0.74% | -9.0% |
| Q2 2013 | $1,122,000 | – | 16,200 | – | 0.81% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |